WSR 22-10-044
(Pharmacy Quality Assurance Commission)
[Filed April 28, 2022, 6:57 a.m., effective May 29, 2022]
Effective Date of Rule: Thirty-one days after filing.
Purpose: WAC 246-945-056 Schedule V. The pharmacy quality assurance commission (commission) is amending WAC 246-945-056 to delete Epidiolex from Schedule V controlled substances in Washington state to be in line with federal changes in the Uniform Controlled Substances Act and in response to a rule-making petition received on April 7, 2020. The commission has filed consecutive emergency rules to stay in alignment with the federal changes until this permanent rule is adopted. When it becomes effective, this rule will supersede the current emergency rule under WSR 22-06-053 filed on February 25, 2022.
Citation of Rules Affected by this Order: Amending WAC 246-945-056.
Statutory Authority for Adoption: RCW 18.64.005, 69.50.201.
Adopted under notice filed as WSR 22-05-089 on February 15, 2022.
Number of Sections Adopted in Order to Comply with Federal Statute: New 0, Amended 0, Repealed 0; Federal Rules or Standards: New 0, Amended 1, Repealed 0; or Recently Enacted State Statutes: New 0, Amended 0, Repealed 0.
Number of Sections Adopted at the Request of a Nongovernmental Entity: New 0, Amended 0, Repealed 0.
Number of Sections Adopted on the Agency's own Initiative: New 0, Amended 0, Repealed 0.
Number of Sections Adopted in Order to Clarify, Streamline, or Reform Agency Procedures: New 0, Amended 0, Repealed 0.
Number of Sections Adopted using Negotiated Rule Making: New 0, Amended 0, Repealed 0; Pilot Rule Making: New 0, Amended 0, Repealed 0; or Other Alternative Rule Making: New 0, Amended 1, Repealed 0.
Date Adopted: March 25, 2022.
Teri Ferreira, RPh
Pharmacy Quality Assurance Chair
AMENDATORY SECTION(Amending WSR 20-12-072, filed 6/1/20, effective 7/1/20)
WAC 246-945-056Schedule V.
The commission finds that the following substances have low potential for abuse relative to substances in Schedule IV under RCW 69.50.210 and WAC 246-945-055 and have currently accepted medical use in treatment in the United States and that the substances have limited physical dependence or psychological dependence liability relative to the substance in Schedule IV. In addition to the substances listed in RCW 69.50.212, the commission places each of the following drugs and substances by whatever official name, common or usual name, chemical name, or brand name in Schedule V.
Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
(1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide); also referred to as BRV; UCB-34714; Briviact;
(2) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester].
(((3) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols, also known as Epidiolex.))